8-K - Spectral AI, Inc. (0001833498) (Filer)

8-K - Spectral AI, Inc. (0001833498) (Filer)

8-K - Spectral AI, Inc. (0001833498) (Filer)

SCHEDULE 13G/A - Spectral AI, Inc. (0001833498) (Subject)

8-K - Spectral AI, Inc. (0001833498) (Filer)

DEFA14A - Spectral AI, Inc. (0001833498) (Filer)

DEF 14A - Spectral AI, Inc. (0001833498) (Filer)

8-K - Spectral AI, Inc. (0001833498) (Filer)

PRE 14A - Spectral AI, Inc. (0001833498) (Filer)

8-K - Spectral AI, Inc. (0001833498) (Filer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

4 - Spectral AI, Inc. (0001833498) (Issuer)

BTIG Research initiated coverage of Spectral AI with a rating of Buy and set a new price target of $4.00

DALLAS, July 08, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Darcy Bajko as Chief Commercial Officer, effective July 31, 2026. Ms. Bajko will lead the commercial functions in support of Spectral AI’s global launch of its DeepView® System for burn indication, which was granted De Novo Classification by the U.S. Food and Drug Administration (FDA) in May 2026. "Darcy’s appointment further strengthens our executive team and represents an important step for Spectral AI as we pivot

DALLAS, June 25, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today reflected on its successful participation at the British Burn Association (BBA) Annual Conference, held on June 17th – 19th  at the Nottingham Trent University, Nottingham, England.    The Company’s DeepView® System was on display and was the subject of multiple podium and poster presentations during the conference, highlighting its contributions to advancing burn care through advanced diagnostic analysis across the globe. The presentation fr

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, is joining the American Board of Wound Management (ABWM) Foundation in celebrating the 10th Annual Wound Healing Awareness Month. In this milestone year, during the month of June the ABWM Foundation will continue its mission of raising awareness, empowering certified wound care specialists, and transforming lives. "Wound Healing Awareness Month is an important reminder that patients living with painful, sometimes complex burn wounds require a timely

DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its participation in the upcoming British Burn Association ("BBA") Annual Meeting, being held June 17-19, 2026 at the Nottingham Trent University, Nottingham, England.    The Company's DeepView® System will be on display at Stand #22 and will be the subject of multiple podium and poster presentations during the conference. This innovative, first-of-its-kind burn wound assessment technology was granted De Novo Classification by the U.S

DALLAS, June 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2026 Annual Meeting of Stockholders, held on May 29, 2026. The Company also provided an overview of its accomplishments to date and targeted milestones for 2026 following the receipt of De Novo Classification for its DeepView® System from the U.S. Food and Drug Administration ("FDA"). 2026 Annual Meeting of Stockholders A total of 17,267,570 shares representing 54.3% of the Company's total shares outstanding were re

DALLAS, May 26, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the U.S. Food and Drug Administration (FDA) granted De Novo Classification for its DeepView® System. With this classification, Spectral AI is authorized to commence commercial distribution activities in the United States. The DeepView System is intended for use in burn care in various settings, including burn centers, trauma centers, and emergency departments. "We are pleased that the FDA has recognized our novel technology. I a

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from traffic enforcement and occupational safety to clinical medicine and public health. Conventional tools such as breathalyzers, blood draws and urine tests are hampered by their intrusiveness, slow turnaround times or inability to capture real-time impairment, especially when multiple substances are involved. As substance-use patterns shift and the broader societal costs of intoxication continue to mount, the pressure to develop faster, less invasive, and more scalable detection methods is intensifyi

Development Work for DeepView® Systems Continues with Support of Recently Awarded $31.7 Million of Funding from BARDA Reiterates Annual Revenues Guidance DALLAS, May 12, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2026. "Our results for the 2026 first quarter reflected the progress we have made in developing our DeepView® System for burn indication under the base phase of our Project BioShield Contract with BARDA," said Vincent Capone, Chief

DALLAS, April 30, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has received the "Small Business Innovator Award" at the inaugural Texas Innovation Conference, held on April 22-23, 2026 at the campus of Texas Christian University. The conference highlighted organizations and thought leaders that are turning research into real-world results, bringing together a select group of high-impact innovators, including startups, researchers, and ecosystem leaders. The Texas Innovation Awards ceremo

DALLAS, April 28, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the first quarter ended March 31, 2026 on Tuesday, May 12, 2026 after the close of the Nasdaq stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time on the same day to discuss its financial results. Investors interested in participating in the live call can dial into the conference call as follows: 833-890-6620 – U.S.412-564-3789 – International In addit

DALLAS, July 08, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Darcy Bajko as Chief Commercial Officer, effective July 31, 2026. Ms. Bajko will lead the commercial functions in support of Spectral AI’s global launch of its DeepView® System for burn indication, which was granted De Novo Classification by the U.S. Food and Drug Administration (FDA) in May 2026. "Darcy’s appointment further strengthens our executive team and represents an important step for Spectral AI as we pivot

DALLAS, June 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2026 Annual Meeting of Stockholders, held on May 29, 2026. The Company also provided an overview of its accomplishments to date and targeted milestones for 2026 following the receipt of De Novo Classification for its DeepView® System from the U.S. Food and Drug Administration ("FDA"). 2026 Annual Meeting of Stockholders A total of 17,267,570 shares representing 54.3% of the Company's total shares outstanding were re

DALLAS, April 08, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of David McGuire as the Company's Chief Financial Officer, effective May 4, 2026. "David's appointment as CFO is another important step in strengthening Spectral AI's financial leadership and strategic readiness as we prepare for commercialization of the DeepView® System," said Vincent S. Capone, Spectral AI's Chief Executive Officer. "David is a seasoned public company executive with experience in global markets, fin

DALLAS, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the Company's Board of Directors has appointed Vincent S. Capone as Chief Executive Officer of the Company, effective February 9, 2026. The appointment of Mr. Capone, who currently serves as the Company's Chief Financial Officer and General Counsel, comes as Spectral AI transitions towards commercialization of its proprietary, non-invasive, AI-driven burn wound assessment device – the DeepView® System. "Vince brings a unique set

DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Stanley Micek has been named the Company's Chief Operating Officer ("COO"). Micek's promotion reflects his role change from Interim COO of the Company since May, 2024 "Stan has demonstrated exceptional leadership, operational insight, and a deep understanding of our business during his time as interim COO," said Dr. J. Michael DiMaio, M.D., Chairman of the Company's Board of Directors. "His efforts leading our Research and Devel

DALLAS, May 29, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announced results from its 2025 Annual Meeting of Stockholders held earlier today. A total of 15,551,068 shares representing 60.8% of the Company's total shares outstanding were represented at the meeting, either in person or by proxy. Both of the proposals set forth by the Company were approved by its stockholders. The voting results are detailed below. Six directors were elected to serve on the Company's Board of Directors until the next Annual Me

DALLAS, May 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective following the closing of US equity markets on Friday, June 28, 2024 according to a preliminary list of additions posted Friday, May 24, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, 2024 ranking them by total market capitalization. Members

DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2024 Annual Meeting of Stockholders held on May 14, 2024 (the "AGM"). At the AGM, stockholders overwhelmingly approved each of the four proposals set forth by the Company. The voting results are detailed below. Six directors were elected to serve until the next Annual Meeting of Stockholders: Richard Cotton, Chairman of the Company's Board of DirectorsPeter M. Carlson, Chief Executive Officer of the

DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer. Jeremiah has more than 20 years of medical device marketing experience, including global marketing and business strategy. Mr. Sparks will be responsible for both domestic and international product commercialization. "We are thrilled to have Jeremiah join the company as we move towards commercialization of DeepView," said Peter M. Carlson, CEO of Spectral AI.

Appointment Paves the Way for Company's Next Chapter in Commercialization Phase of AI-Powered DeepView Device for Predictive Wound Care Carlson Brings Proven Track Record of Operating and Financial Leadership, Including with Premier Wound Care Management Companies Wensheng Fan Transitions to Chief Innovation Strategist and Senior Advisor to the CEO Company Announces Preliminary 2023 R&D Revenue; Reaffirms Full Year Revenue Guidance for 2024 and Highlights First Quarter Momentum DALLAS, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate tre

SC 13G/A - Spectral AI, Inc. (0001833498) (Subject)

SC 13G/A - Spectral AI, Inc. (0001833498) (Subject)

SC 13D/A - Spectral AI, Inc. (0001833498) (Subject)

SC 13D/A - Spectral AI, Inc. (0001833498) (Subject)

Development Work for DeepView® Systems Continues with Support of Recently Awarded $31.7 Million of Funding from BARDA Reiterates Annual Revenues Guidance DALLAS, May 12, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2026. "Our results for the 2026 first quarter reflected the progress we have made in developing our DeepView® System for burn indication under the base phase of our Project BioShield Contract with BARDA," said Vincent Capone, Chief

DALLAS, April 28, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the first quarter ended March 31, 2026 on Tuesday, May 12, 2026 after the close of the Nasdaq stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time on the same day to discuss its financial results. Investors interested in participating in the live call can dial into the conference call as follows: 833-890-6620 – U.S.412-564-3789 – International In addit

Overview Full Year Research & Development Revenue of $19.7 Million; Q4 2025 Revenue of $3.8 MillionCash Rose to $15.4 Million at December 31, 2025 DALLAS, March 24, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence ("AI") company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter ("Q4 2025") and full year ("FY 2025") ended December 31, 2025 and provided an update on its ongoing activities related to the commercialization of its proprietary, AI-driven DeepView® System for burn indication. "2025 was a pivotal year fo

DALLAS, March 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2025 on Tuesday, March 24, 2026 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the results. Investors interested in participating in the live call can dial: 833-890-6620 – U.S.412-564-3789 – International A simultaneous webcast of the call may be access

Q3 Overview Research & Development Revenue of $3.8 Million; $15.6 Million in YTD Revenue for 2025Strong Cash position of $10.5 Million and progress toward FDA De Novo submission DALLAS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the third quarter ended September 30, 2025 and provided an update on its ongoing business activities. The Company maintained a strong cash position of $10.5 million, recorded $3.8 million in research and development revenue, and continue

DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the third quarter ended September 30, 2025 on Tuesday, November 11, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the results. Investors interested in participating in the live call can dial: 833-630-1956 – U.S.412-317-1837 – International A simultaneous webcast of the call may be accessed online fr

Q2 Overview Research & Development Revenue of $5.1 Million, total revenue for the first half of 2025 of $11.8 MillionStrong Cash position of $10.5 MillionSubmission of De Novo application to FDA completed in Second Quarter of 2025 DALLAS, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the second quarter ended June 30, 2025 and provided an update on its ongoing business activities. "We are pleased with the results of our second quarter of 2025 especially with our ab

DALLAS, July 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ:MDAI) ("Spectral AI" or the "Company"), developer of the AI-driven DeepView® System and focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the second quarter ended June 30, 2025 on Tuesday, August 12, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the results. Investors interested in participating in the live call can dial: 833-630-1956 – U.S.412-317-1837 – International A simultaneous webcast of the call may be accessed online

Q1 Overview Research & Development Revenue of $6.7 MillionImproved Capital Structure Reflected in Cash of $14.1 MillionContinued work on planned De Novo submission to the FDA in the first half of 2025 DALLAS, May 13, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2025 and provided an update on its ongoing business activities. "During the first quarter we continued to execute against our strategic plan and are working hard towards our De Nov

DALLAS, May 02, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ:MDAI) ("Spectral AI" or the "Company"), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential today announced that it will report financial results for the first quarter ended March 31, 2025 on Tuesday, May 13, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results. Investors interested in participating in the live call can dial: 833-630-1956 - U.S.412-317-1837 - International A simultaneous webcast of the call may be accessed online from the Events